166. Pseudoxanthoma elasticum Clinical trials / Disease details
Clinical trials : 15 / Drugs : 27 - (DrugBank : 5) / Drug target genes : 5 - Drug target pathways : 28
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT00510965 (ClinicalTrials.gov) | August 2007 | 1/8/2007 | Ranibizumab to Treat Choroidal Neovascularization (CNV) in Patients With Pseudoxanthoma Elasticum (PXE) | Ranibizumab in Choroidal Neovascularization (CNV) Due to Pseudoxanthoma Elasticum (PXE, Groenblad-Strandberg-Syndrome) | Choroidal Neovascularization | Drug: Intravitreal injection ranibizumab | University Hospital, Bonn | Novartis | Completed | 18 Years | 65 Years | Both | 10 | Phase 2 | Germany |